Follow Us

header ads
header ads

Digital Biomarkers Market Global Sales Are Expected To Reach $ 14.58 Bn by 2030

The global digital biomarkers market size is expected to reach around US$ 14.58 billion by 2030 from US$ 1.57 billion in 2021 and is expected to grow at an impressive double-digit rate of  28.1% from 2021 to 2030.

Digital Biomarkers Market Size 2020 to 2030

The global digital biomarkers market is primarily driven by the rising usage of the digital biomarkers across various applications such as diabetes, respiratory diseases, CVDs, and sleep disorders.

The study includes drivers and restraints of this market. The study provides an analysis of the global digital biomarkers market for the period 2017-2030, wherein 2021 to 2030 is the forecast period and 2020 is considered as the base year.

Download Free Sample Copy Here (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1537

Some of the prominent players in the global digital biomarkers market include:

  • Bayer AG
  • Biogen Inc.
  • ActigraphLLc
  • Amgen Inc
  • F. Hoffmann-La Roche Ltd
  • Fitbit Inc
  • GlaxoSmithKline Plc
  • Koninklijke Philips N.V.
  • Mindstrong Health
  • Medical Care Corporation
  • Medopad Ltd

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Why should you invest in this report?

If you are aiming to enter the global digital biomarkers market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for digital biomarkers are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030, so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Segments Covered in the Report

By System Component

  • Data Collection Tools
    • Mobile Apps
    • Wearable
    • Digital Platforms
    • Biosensors
    • Desktop-Based Software
  • Data Integration Systems

By Application

  • Sleep & Movement Disease
  • Cardiovascular Diseases
  • Respiratory Disease
  • Neurodegenerative Disorders
  • Diabetes
  • Gastrointestinal Disease
  • Psychiatric Disorder
  • Others

Regional Analysis:

The geographical analysis of the global digital biomarkers market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.

The North American Market is again segmented into the US, Canada, and Mexico. Coming to the European Market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global digital biomarkers Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).

Key Questions Answered by the Report:

  • What will be the size of the global digital biomarkers market in 2030?
  • What is the expected CAGR for the digital biomarkers market between 2021 and 2030?
  • Which are the top players active in this global market?
  • What are the key drivers of this global market?
  • How will the market situation change in the coming years?
  • Which region held the highest market share in this global market?
  • What are the common business tactics adopted by players?
  • What is the growth outlook of the global digital biomarkers market?

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Digital Biomarkers Market 

5.1. COVID-19 Landscape: Digital Biomarkers Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Digital Biomarkers Market, By System Component

8.1. Digital Biomarkers Market, by System Component Type, 2021-2030

8.1.1. Data Collection Tools

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Data Integration Systems

8.1.2.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Digital Biomarkers Market, By Application

9.1. Digital Biomarkers Market, by Application, 2021-2030

9.1.1. Sleep & Movement Disease

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Cardiovascular Diseases

9.1.2.1. Market Revenue and Forecast (2019-2030)

9.1.3. Respiratory Disease

9.1.3.1. Market Revenue and Forecast (2019-2030)

9.1.4. Neurodegenerative Disorders

9.1.4.1. Market Revenue and Forecast (2019-2030)

9.1.5. Diabetes

9.1.5.1. Market Revenue and Forecast (2019-2030)

9.1.6. Gastrointestinal Disease

9.1.6.1. Market Revenue and Forecast (2019-2030)

9.1.7. Psychiatric Disorder

9.1.7.1. Market Revenue and Forecast (2019-2030)

9.1.8. Others

9.1.8.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Digital Biomarkers Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by System Component (2019-2030)

10.1.2. Market Revenue and Forecast, by Application (2019-2030)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by System Component (2019-2030)

10.1.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by System Component (2019-2030)

10.1.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.2. Europe

10.2.1. Market Revenue and Forecast, by System Component (2019-2030)

10.2.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by System Component (2019-2030)

10.2.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by System Component (2019-2030)

10.2.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by System Component (2019-2030)

10.2.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by System Component (2019-2030)

10.2.6.2. Market Revenue and Forecast, by Application (2019-2030)

10.3. APAC

10.3.1. Market Revenue and Forecast, by System Component (2019-2030)

10.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by System Component (2019-2030)

10.3.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by System Component (2019-2030)

10.3.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by System Component (2019-2030)

10.3.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by System Component (2019-2030)

10.3.6.2. Market Revenue and Forecast, by Application (2019-2030)

10.4. MEA

10.4.1. Market Revenue and Forecast, by System Component (2019-2030)

10.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by System Component (2019-2030)

10.4.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by System Component (2019-2030)

10.4.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by System Component (2019-2030)

10.4.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by System Component (2019-2030)

10.4.6.2. Market Revenue and Forecast, by Application (2019-2030)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by System Component (2019-2030)

10.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by System Component (2019-2030)

10.5.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by System Component (2019-2030)

10.5.4.2. Market Revenue and Forecast, by Application (2019-2030)

Chapter 11. Company Profiles

11.1. Bayer AG

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Biogen Inc.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. ActigraphLLc

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Amgen Inc

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. F. Hoffmann-La Roche Ltd

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Fitbit Inc

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. GlaxoSmithKline Plc

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Koninklijke Philips N.V.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Mindstrong Health

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Medical Care Corporation

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1537

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://precedenceresearchnews.wordpress.com

Follow us on LinkedIn | Twitter | Facebook

Post a Comment

0 Comments